These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35988291)

  • 1. Oligonucleotide-based therapies for cystic fibrosis.
    Kreda SM
    Curr Opin Pharmacol; 2022 Oct; 66():102271. PubMed ID: 35988291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of CFTR modulators for the treatment of cystic fibrosis.
    Lopes-Pacheco M; Pedemonte N; Veit G
    Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
    Fajac I; Sermet-Gaudelus I
    Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
    Burgener EB; Moss RB
    Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived cell models for personalized medicine approaches in cystic fibrosis.
    Ramalho AS; Amato F; Gentzsch M
    J Cyst Fibros; 2023 Mar; 22 Suppl 1(Suppl 1):S32-S38. PubMed ID: 36529661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis: a model system for precision medicine.
    Martiniano SL; Sagel SD; Zemanick ET
    Curr Opin Pediatr; 2016 Jun; 28(3):312-7. PubMed ID: 27031658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating the genetics of cystic fibrosis to personalized medicine.
    Corvol H; Thompson KE; Tabary O; le Rouzic P; Guillot L
    Transl Res; 2016 Feb; 168():40-49. PubMed ID: 25940043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theratyping in cystic fibrosis.
    Crawford KJ; Downey DG
    Curr Opin Pulm Med; 2018 Nov; 24(6):612-617. PubMed ID: 30124524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis.
    Michaels WE; Pena-Rasgado C; Kotaria R; Bridges RJ; Hastings ML
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017302
    [No Abstract]   [Full Text] [Related]  

  • 14. Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives.
    Kim YJ; Krainer AR
    Mol Cells; 2023 Jan; 46(1):10-20. PubMed ID: 36697233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CFTR modulator theratyping: Current status, gaps and future directions.
    Clancy JP; Cotton CU; Donaldson SH; Solomon GM; VanDevanter DR; Boyle MP; Gentzsch M; Nick JA; Illek B; Wallenburg JC; Sorscher EJ; Amaral MD; Beekman JM; Naren AP; Bridges RJ; Thomas PJ; Cutting G; Rowe S; Durmowicz AG; Mense M; Boeck KD; Skach W; Penland C; Joseloff E; Bihler H; Mahoney J; Borowitz D; Tuggle KL
    J Cyst Fibros; 2019 Jan; 18(1):22-34. PubMed ID: 29934203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new era of personalized medicine for cystic fibrosis - at last!
    Quon BS; Wilcox PG
    Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.
    Becq F
    Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
    Ensinck MM; Carlon MS
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
    Mall MA; Mayer-Hamblett N; Rowe SM
    Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.